Lumos Diagnostics Holdings Limited (ASX:LDX)

Market Cap	68.99M -49.9%
Revenue (ttm)	19.07M +6.4%
Net Income	-7.16M
EPS	-0.01
Shares Out	971.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	681,928
Open	0.0750
Previous Close	0.0730
Day's Range	0.0700 - 0.0750
52-Week Range	0.0550 - 0.3300
Beta	0.53
Analysts	n/a
Price Target	0.28 (+287.32%)
Earnings Date	Oct 27, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LDX

Financial Performance

In fiscal year 2026, ASX:LDX's revenue was $13.19 million, an increase of 6.39% compared to the previous year's $12.40 million. Losses were -$4.95 million, -31.06% less than in 2025.

Financial numbers in USD

Analyst Summary

The average 12-month stock price target for LDX is $0.28, which is an increase of 287.32% from the latest price.

Price Target

$0.28

(287.32% upside)

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error